top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 5 hours ago
  • 1 min read

21/02/2026



























Three-year data demonstrated sustained clinical and endoscopic remission in ulcerative colitis with guselkumab (Ref)


  • Johnson & Johnson announced new long-term data from the Phase 2b/3 QUASAR/ NCT04033445 study evaluating TREMFYA® (guselkumab; anti-IL-23) in adult patients with moderately-to-severely active ulcerative colitis (UC)


  • In this study, guselkumab showed sustained clinical, endoscopic, and histologic outcomes through Week 140


  • At week 140:


    • 80.8% of patients were in clinical remission


    • 53.6% of patients were in endoscopic remission


    • 78.6% of patients achieved histo-endoscopic mucosal improvement, indicating intestinal healing at both the tissue and visual level



bottom of page